Lower response to trastuzumab emtansine in metastatic breast cancer patients with human epidermal growth factor receptor 2 immunohistochemistry score of 2 and fluorescence in situ hybridization positive compared with immunohistochemistry score of 3: a retrospective study-Reference-Cited by-同舟云学术

Lower response to trastuzumab emtansine in metastatic breast cancer patients with human epidermal growth factor receptor 2 immunohistochemistry score of 2 and fluorescence in situ hybridization positive compared with immunohistochemistry score of 3: a retrospective study

Published:2020-08-27 Issue:9 Volume:31 Page:973-978
ISSN:0959-4973
Container-title:Anti-Cancer Drugs
language:en
Short-container-title:

Author:

Yazaki Shu,Hashimoto Jun,Ogita Shin,Nakano Eriko,Suzuki Koyu,Yamauchi Teruo

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology (medical),Pharmacology,Oncology

Reference23 articles.

1. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science.;Slamon,1989

2. Comparative analysis of human epidermal growth factor receptor 2 testing in breast cancer according to 2007 and 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations.;Hanna;J Clin Oncol,2017

3. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.;Slamon;N Engl J Med,2001

4. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.;Swain;N Engl J Med,2015

5. Trastuzumab emtansine for HER2-positive advanced breast cancer.;Verma;N Engl J Med,2012

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trastuzumab deruxtecan in breast cancer;Critical Reviews in Oncology/Hematology;2024-06

2. Biology and Treatment of HER2-Low Breast Cancer;Hematology/Oncology Clinics of North America;2023-02

3. Impacts of HER2 immunohistochemical scores on response and outcomes of HER2-positive breast cancers after neoadjuvant therapy;Journal of the Chinese Medical Association;2023-01-23

4. Comparison of clinicopathological characteristics and response to neoadjuvant systemic therapy in patients with HER2-low-positive and HER2-zero breast cancer;Journal of Investigative Medicine;2023-01-19

5. HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer;Frontiers in Molecular Biosciences;2022-03-15